A call to action for COPD, a silent epidemic that needs global attention urgently: Today on World COPD Day a coalition of advocates and industry say we can no longer afford to ignore the third-leading cause of death worldwide.
Canada: Persistent hypoxemia requiring short-term oxygen therapy (STOT) following an acute respiratory illness in COPD is a marker of disease progression to long-term oxygen therapy (LTOT), states a.
Published: Apr 21, 2021
Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) in a single device.
With this new European authorization, Chiesi reinforces its commitment to providing a broad portfolio of formulations and devices to COPD patients.
PARMA, Italy, April 21, 2021 (GLOBE NEWSWIRE) Chiesi, an international research-focused healthcare group (Chiesi Group), today announced that the European Commission has granted the marketing authorization for Trimbow® inhalation powder delivered through NEXThaler (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium), an extrafine formulation triple fixed combination therapy in a single dry powder inhaler (DPI), for the maintenance treatment in adult patients wit